Proteomic approaches in the search for biomarkers of liver fibrosis

Chronic liver diseases (CLDs) can cause progressive hepatic fibrosis culminating in cirrhosis. Fibrosis staging requires liver biopsy, which is invasive, expensive and frequently poorly tolerated by patients. Serum-based panels of fibrosis biomarkers have been developed as alternatives to biopsy. Re...

Full description

Saved in:
Bibliographic Details
Published inTrends in molecular medicine Vol. 16; no. 4; pp. 171 - 183
Main Authors Cowan, Matthew L, Rahman, Tony M, Krishna, Sanjeev
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2010
Subjects
Biomarkers - blood
Chronic Disease
Diagnosis, Differential
Humans
Liver Cirrhosis - blood
Liver Cirrhosis - diagnosis
Liver Cirrhosis - pathology
Pathology
Proteomics - methods
Online AccessGet full text

Cover

More Information
Summary:Chronic liver diseases (CLDs) can cause progressive hepatic fibrosis culminating in cirrhosis. Fibrosis staging requires liver biopsy, which is invasive, expensive and frequently poorly tolerated by patients. Serum-based panels of fibrosis biomarkers have been developed as alternatives to biopsy. Recent advances in high-throughput proteomic methods have the potential to optimise combinations of biomarkers for the diagnosis of liver fibrosis. Here, we review the key recent developments in the field of proteomics and their application to this important clinical question. We critically discuss the challenges and priorities for future research that are of critical importance to clinical hepatology.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2010.01.006